Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Osteopore Ltd. ( (AU:OSX) ) has provided an announcement.
Osteopore Limited has signed an exclusive three-year distribution agreement, with an option for a one-year extension, with MontsMed Hong Kong Company Limited to introduce its custom and off-the-shelf orthopaedic products into Hong Kong, initially targeting the orthopaedic trauma reconstruction market where its devices have the strongest application potential. While Hong Kong is a relatively small market, Osteopore’s move positions the company in a strategically important hub to access the Greater Bay Area and benefit from emerging regulatory harmonisation for medical devices across China’s regional healthcare network, aligning the business with a fast-growing Asia-Pacific bone graft and substitutes market projected to expand at an 8.2% CAGR through 2030.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
More about Osteopore Ltd.
Osteopore Limited is an Australian-Singaporean regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants, supplying custom and off-the-shelf products for orthopaedic and trauma reconstruction markets in regions including Europe, Singapore and Vietnam.
Average Trading Volume: 7,111,270
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.39M
Learn more about OSX stock on TipRanks’ Stock Analysis page.